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Should statins be a part of the sepsis treatment regimen? 
Not yet, suggest Terblanche and colleagues [1] in the 
previous issue of Critical Care. Pleiotropic eﬀ  ects beyond 
cholesterol reduction have been reported in statins [2-5]. 
Th  ese  anti-inﬂ   ammatory and immuno  modu  latory 
eﬀ  ects, seen in models of sepsis and acute lung injury 
(ALI), provide the basis for statin therapy in critically ill 
patients [6-10]. Observational data regarding the 
potential beneﬁ  cial pleiotropic eﬀ  ects of statins in sepsis 
and ALI have been presented, and ﬁ  ndings  variously 
support and refute the beneﬁ  cial eﬀ  ects of statins in the 
infected patient. While meta-analysis suggests a potential 
beneﬁ  t, the few prospective random  ized trials that have 
been published have conﬂ  ict  ing conclusions [11-13].
Th  e retrospective study by Terblanche and colleagues 
[1], who followed mechanically ventilated patients 
without signiﬁ   cant non-pulmonary end-organ disease 
over their intensive care unit (ICU) stay, adds to the con-
tro  versy. Patients receiving statins had higher APACHE II 
(Acute Physiology and Chronic Health Evaluation II) 
scores (20.3 versus 17.8; P <0.0001) and were older (67.4 
versus 55.5 years; P <0.0001). Th   ose receiving statins also 
had more severe respiratory SOFA (Sepsis-related Organ 
Failure Assessment) scores and were more likely to have 
some degree of renal and cardiovascular dysfunction at 
baseline. Statin adminis  tration was not associated with 
reduced incidence of non-pulmonary acute organ failure 
or mortality but was associated with longer ICU and 
hospital stays. A greater proportion of the statin group 
had alanine amino  transferase (ALT) values of greater 
than three times the upper limit of normal (ULN) (11.6% 
versus 4.8%; P = 0.0002). Th  ese elevations were brief in 
longevity, and no clinical untoward eﬀ  ects were noted. It 
is diﬃ   cult to understand the ramiﬁ  cations, as the median 
time of drug delivery was just 3  days, limiting both 
beneﬁ  cial eﬀ  ects and harmful ones. Th   e median dose of 
simvastatin, the predominant statin, was just 20 mg, and 
only one third of patients had statins started on day 1; 
both circumstances potentially reduced the opportunity 
to prevent the progres  sion of organ dysfunction.
Kruger and colleagues [14] randomly assigned patients 
on statins after admission for sepsis to atorvastatin 20 mg 
(equivalent to simvastatin 40 mg) or placebo. Patients 
were admitted to either acute care wards or ICUs, 
whereas patients in the study by Terblanche and colleagues 
were admitted to the ICU or were mechanically venti-
lated. Continuation of statin therapy was not protective 
with regard to sepsis or markers of inﬂ  ammation. 
Compared with subjects in the study by Terblanche and 
colleagues, subjects received more doses of study drug, 
and 3 out of 150 patients had an elevated ALT of greater 
than ﬁ  ve times the ULN. Two of the three were receiving 
atorvastatin. No patients had creatine kinase (CK) values 
exceeding 10 times the ULN. Kruger and the Australian 
and New Zealand Intensive Care Society (ANZICS) have 
just concluded a study randomly assigning ICU patients 
with severe sepsis to atorvastatin or placebo 
(ACTRN12607000028404).
Craig and colleagues [15] evaluated patients with ALI 
from all causes and randomly assigned 60 patients to 
simvastatin 80 mg/day or placebo until extubation or 
14 days, whichever occurred ﬁ  rst. While this study was 
not powered to detect diﬀ   erences in mortality, a 
signiﬁ  cant reduction in SOFA scores was noted at day 14, 
suggesting that statin administration hastens the 
resolution of end-organ damage. SOFA scores fell from 
10.2 to 4.2 in the statin group and from 10.4 to 8.8 in the 
placebo group (P = 0.01). Doses were administered 88% 
and 82% of days in the statin and placebo groups, 
respectively, and no diﬀ  erences in elevated CK, ALT, or 
Abstract
Terblanche and colleagues add to the ongoing 
controversy over the role, if any, for statins in patients 
with sepsis. The authors note that statins fail to prevent 
progression to organ dysfunction in critically ill 
patients. However, like most publications, the study is 
retrospective and stimulates the controversy but fails 
to resolve it. The time has come for robust randomized 
controlled clinical trials.
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were noted. Th  is population had higher APACHE II 
scores than those in the study by Terblanche and 
colleagues, and mean values were 25.1 and 23.3 in the 
statin and placebo groups, respectively. Daniel McAuley 
and the Irish Critical Care Trials Group have initiated a 
larger randomized controlled trial that has ventilator-free 
days (VFDs) as the primary outcome (ISRCTN88244364).
Th   e National Heart, Lung, and Blood Institute (NHLBI) 
ARDSNet has initiated the SAILS (Statins for Acutely 
Injured Lungs from Sepsis) trial (NCT00979121). In this 
study, subjects who have ALI and who are statin-free for 
72 hours are randomly assigned to rosuvastatin 20 mg 
(equivalent to simvastatin 80 mg) or placebo. Th  e 
primary outcome is mortality, and secondary outcomes 
include VFDs, organ failure-free days, ICU-free days, and 
toxicity.
Some questions regarding statin administration in 
patients with presumed infections and systemic 
inﬂ  ammatory response syndrome, sepsis, severe sepsis, 
or ALI remain unanswered:
1. Can statins reduce mortality?
2. Are statins eﬀ  ective in preventing or reducing severity 
of end-organ damage?
3. Are statins eﬀ  ective in hastening the resolution of end-
organ damage?
4. If the answer to any of these questions is yes, then
a. Which statin is most eﬀ  ective and safest?
b. What dose is most eﬀ  ective and safest?
c. Do patients have to be on maintenance statins 
before developing critical illness?
It is time to turn away from retrospective and obser-
vational studies or meta-analysis and test the plausible 
rationales that have been put forth. Indeed, several 
randomized clinical trials have been initiated to address 
some of these questions in patients with sepsis or ALI.
Abbreviations
ALI, acute lung injury; ALT, alanine aminotransferase; APACHE II, Acute 
Physiology and Chronic Health Evaluation II; CK, creatine kinase; ICU, intensive 
care unit; SOFA, Sepsis-related Organ Failure Assessment; ULN, upper limit of 
normal; VFD, ventilator-free day.
Competing interests
JDT is the principal investigator for the SAILS trial mentioned above.
Published: 31 March 2011
References
1.  Terblanche MJ, Pinto R, Whiteley C, Brett S, Beale R, Adhikari NKJ: Statins do 
not prevent acute organ failure in ventilated ICU patients: single-centre 
retrospective cohort study. Crit Care 2011, 15:R74.
2.  Liao JK, Laufs U: Pleiotropic eff  ects of statins. Annu Rev Pharmacol Toxicol 
2005, 45:89-118.
3. Weitz-Schmidt  G:  Statins as anti-infl  ammatory agents. Trends Pharmacol Sci 
2002, 23:482-486.
4.  Gao F, Linhartova L, Johnston AM, Thickett DR: Statins and sepsis. Br J 
Anaesth 2008, 100:288-298.
5.  Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG: Statins: panacea 
for sepsis? Lancet Infect Dis 2006, 6:242-248.
6.  Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG: 
Simvastatin attenuates vascular leak and infl  ammation in murine 
infl  ammatory lung injury. Am J Physiol Lung Cell Mol Physiol 2005, 
288:L1026-1032.
7.  Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, 
Hanrath P, Weber C: Statin treatment after onset of sepsis in a murine 
model improves survival. Circulation 2005, 112:117-124.
8.  Mueller HC, Hellwig K, Rosseau S, Tschernig T, Schmiedl A, Gutbier B, Schmeck 
B, Hippenstiel S, Peters H, Morawietz L, Suttorp N, Witzenrath M: Simvastatin 
attenuates ventilator-induced lung injury in mice. Crit Care 2010, 14:R143.
9.  Jain MK, Ridker PM: Anti-infl  ammatory eff  ects of statins: clinical evidence 
and basic mechanisms. Nat Rev Drug Discov 2005, 4:977-987.
10.  Shyamsundar M, McKeown ST, O’Kane CM, Craig TR, Brown V, Thickett DR, 
Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF: Simvastatin 
decreases lipopolysaccharide-induced pulmonary infl  ammation in 
healthy volunteers. Am J Respir Crit Care Med 2009, 179:1107-1114.
11.  Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J: The eff  ect of statins 
on mortality from severe infections and sepsis: a systematic review and 
meta-analysis. J Crit Care 2010, 25:656.e7-22.
12.  Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim 
T: Statins for the prevention and treatment of infections: a systematic 
review and meta-analysis. Arch Intern Med 2009, 169:1658-1667.
13.  Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI: Statins for infection and 
sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 
2008, 61:774-785.
14.  Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, 
Venkatesh B: Continuation of statin therapy in patients with presumed 
infection: a randomised controlled trial. Am J Respir Crit Care Med 2010 Oct 
19. [Epub ahead of print].
15. Craig  TR,  Duff  y MJ, Shyamsundar M, McDowell C, O’Kane C, Elborn JS, 
McAuley DF: A randomized clinical trial of hydroxymethylglutaryl-CoA 
reductase inhibition for acute lung injury (The HARP study). Am J Respir Crit 
Care Med 2010 Sep 24. [Epub ahead of print].
doi:10.1186/cc10086
Cite this article as: Truwit JD: Statins: a role in infected critically ill patients? 
Critical Care 2011, 15:145.
Truwit Critical Care 2011, 15:145 
http://ccforum.com/content/15/2/145
Page 2 of 2